Novel Antibody-Drug Conjugate for CLDN18.2-Positive Gastric and GEJ Cancers
Posted: 11/13/2023 | By: Chase Doyle

A first-in-class, claudin 18.2 (CLDN18.2)-targeted antibody-drug conjugate may be a new treatment option for patients with advanced gastric/gastroesophageal junction (GEJ) cancers, according to data presented by Xu et al during the ASCO Plenary Series: November 2023 Session (Abstract 434420).

Question 1 of 5

CMG901, a potential first-in-class CLDN18.2-targeted antibody-drug conjugate, carries monomethyl auristatin E (MMAE). In International Nonproprietary Names for MMAE-monoclonal antibody conjugates, the name ___ refers to MMAE plus its linking structure to the antibody.

Choose 1